Scleritis Global Market Report 2025

The scleritis market size has grown strongly in recent years. It will grow from $3.6 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of ocular health, a growing geriatric population, improved access to ophthalmic care, and the expansion of healthcare infrastructure worldwide.

The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.54 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the increasing prevalence of eye-related health conditions, rising awareness of ocular health, growing healthcare expenditure, expanding ophthalmology research, increasing demand for personalized medicine, and the development of new treatment options. Key trends include the development of targeted biologic therapies, advancements in immunosuppressive drug formulations, innovations in imaging technologies, the adoption of minimally invasive diagnostic tools, the integration of personalized medicine approaches, improvements in drug delivery systems, and AI-driven diagnostic and treatment planning solutions.

The increasing prevalence of autoimmune diseases is expected to drive the expansion of the scleritis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign threats. The rise in autoimmune diseases is attributed to genetic predispositions, environmental influences, lifestyle changes, and improved diagnostic awareness. These conditions contribute to scleritis by triggering an inflammatory immune response that mistakenly targets scleral tissue, leading to pain and redness. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the growing incidence of autoimmune diseases is fueling the expansion of the scleritis market.

Leading companies in the scleritis market are developing advanced treatments, such as specialized eye drops, to address inflammation and provide non-invasive therapeutic options. Eye drops are liquid formulations designed for direct ocular application to manage conditions such as irritation, dryness, inflammation, and infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, introduced CYCLOTEARS eye drops in India and globally. This innovative treatment for inflammatory eye diseases utilizes proprietary SEDDS technology, enhancing drug delivery and efficacy. The product represents a significant advancement in managing ocular inflammatory conditions, including dry eye disease (DED), ocular myositis, and scleritis.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition grants Regeneron access to an advanced ocular gene therapy delivery system, accelerating its progress toward clinical applications. By integrating Oxular’s proprietary technologies, Regeneron aims to enhance therapeutic precision and drive innovation in eye care. Oxular Limited, a UK-based biotech company, specializes in developing drug and device treatments for eye disorders, including scleritis.

Major players in the scleritis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd., Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West-Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Zydus Pharmaceuticals Inc.

North America was the largest region in the scleritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the scleritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Scleritis is a condition characterized by inflammation of the sclera, the white part of the eye. It is commonly linked to autoimmune diseases and can lead to severe eye pain, redness, and potential vision impairment if left untreated. Proper diagnosis and treatment of scleritis are essential to prevent long-term eye damage. Early medical intervention helps lower the risk of complications, including vision loss.

The primary types of scleritis include anterior scleritis, posterior scleritis, and other forms. Anterior scleritis occurs when the front portion of the sclera, the eye’s outer white layer, becomes inflamed, resulting in redness, pain, and swelling around the eyes. Treatment options include medications, surgical procedures, and other therapies. The condition is addressed through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. Additionally, scleritis treatment is provided in healthcare settings such as hospitals, specialty clinics, home healthcare, and other end-user environments.

The scleritis market research report is one of a series of new reports that provides scleritis market statistics, including the scleritis industry's global market size, regional shares, competitors with a scleritis market share, detailed scleritis market segments, market trends and opportunities, and any further data you may need to thrive in the scleritis industry. This scleritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The scleritis market consists of revenues earned by entities by providing services such as ultrasound, biologic therapies, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleritis market includes sales of ophthalmoscopes, nonsteroidal anti-inflammatory drugs, antibiotics, eye shields or patches, and cold or warm compress kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.